ImmunoCellular Therapeutics (IMUC.OB) issued New Patent
OTCBB: IMUC was issued a patent in France and the UK relating to the treatment and detection of multiple myeloma and ovarian cancer.
- Patent No# 1,204,683 (#683), entitled “Ovarian cancer cells and myeloma cell surface glycoproteins, antibodies” covers aspects of the IMUC.OB’s monoclonal antibody ICT-69, which targets human multiple myeloma and ovarian cancer cells.
The Bottom Line: ICT-69 is already covered in the US and this patent expands coverage of issued patent portfolio to 9. Strengthening the patent portfolio supports the development platforms and enhance their ability to license or partner these platforms.